XOMA | Ticker Profile - Titan Protect

XOMA

XOMA Royalty Corporation

Healthcare · Biotechnology · NGM

$42.09

Data: 2026-05-26

✓ ETHICAL PASS

STRONG MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$522M

Total market value of the company

Trailing P/E

26.53

Premium valuation

Forward P/E

19.46

Based on estimated future earnings — lower means cheaper

Rev Growth

-22.6%

Year-over-year revenue change

Profit Margin

69.6%

How much profit the company keeps from each dollar of revenue

ROE

34.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About XOMA Royalty Corporation

Company description not available.

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

23.9% PASS

Debt must be below 33% of total assets

Cash Ratio

16.5% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$32.10

What our model estimates this business is worth per share

Margin of Safety

-31.1%

Trading above fair value — no margin of safety

Rating

Overall assessment combining ethics, valuation, and quality

Percentile

83.1th

Ranks in the top 17% of our 13,571 screened universe

Ethical Score

N/A

Valuation Score

55.0

Quality Score

73.3

Combined

52.6

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.732

Good returns relative to risk taken

Kelly Fraction

0.0557

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.631

Acceptable balance between returns and drawdown risk

Annual Return

28.2%

Historical annualised return based on price data

Max Drawdown

-44.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.57

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.10

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-26

Before you go